Falcon Point Capital LLC Has $10.03 Million Position in Supernus Pharmaceuticals, Inc. (SUPN)

Falcon Point Capital LLC reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 52.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 232,664 shares of the specialty pharmaceutical company’s stock after selling 255,053 shares during the period. Falcon Point Capital LLC owned about 0.46% of Supernus Pharmaceuticals worth $10,028,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of SUPN. Meeder Asset Management Inc. raised its position in Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 2,315 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter worth $127,000. Fortaleza Asset Management Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter worth $160,000. State of Alaska Department of Revenue raised its position in Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 170 shares in the last quarter. Finally, OppenheimerFunds Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter worth $205,000. 94.39% of the stock is owned by institutional investors and hedge funds.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 41.40 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $17.25 and a 12-month high of $44.95. The stock has a market capitalization of $2.10 billion, a P/E ratio of 20.89 and a beta of 1.31. The company has a 50-day moving average of $42.47 and a 200-day moving average of $34.12.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities analysts expect that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current fiscal year.

WARNING: “Falcon Point Capital LLC Has $10.03 Million Position in Supernus Pharmaceuticals, Inc. (SUPN)” was first reported by Stock Observer and is the property of of Stock Observer. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.thestockobserver.com/2017/08/12/falcon-point-capital-llc-has-10-03-million-position-in-supernus-pharmaceuticals-inc-supn.html.

A number of equities analysts have recently weighed in on the stock. Jefferies Group LLC reissued a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. Piper Jaffray Companies restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Cowen and Company restated a “positive” rating and issued a $50.00 target price (up from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Janney Montgomery Scott initiated coverage on shares of Supernus Pharmaceuticals in a report on Friday, July 14th. They issued a “neutral” rating and a $47.00 target price for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. Supernus Pharmaceuticals presently has an average rating of “Buy” and an average target price of $48.43.

In related news, VP Padmanabh P. Bhatt sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $39.86, for a total transaction of $398,600.00. Following the transaction, the vice president now owns 27,500 shares of the company’s stock, valued at $1,096,150. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $35.90, for a total transaction of $89,750.00. Following the transaction, the vice president now directly owns 37,500 shares in the company, valued at approximately $1,346,250. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,291 shares of company stock worth $962,766. Insiders own 6.70% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply